Inhibition of the growth of human coronavirus 229E by leupeptin.
The protease inhibitor leupeptin prevented multiplication of the human coronavirus strain 229E in cultures of MRC-C cells. The IC50 of leupeptin in plaque reduction tests was 0.4 micrograms/ml, whereas growth of host cells was unaffected by leupeptin at 50 micrograms/ml. Inhibition of plaque formation could be prevented by the addition of proteases to the overlay medium. In single-cycle growth experiments, leupeptin reduced virus yield only if added within 2 h of infection, indicating its action on an early stage of virus replication.
D002460:Cell Line; D003332:Coronaviridae / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology; D006801:Humans; D007976:Leupeptins / Q000494:pharmacology*; D009842:Oligopeptides / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000494:pharmacology; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects
D007976:Leupeptins; D009842:Oligopeptides; D011480:Protease Inhibitors; C032854:leupeptin